• Trabectedin injection should be given directly into the vein through a separate central venous line very slowly for 24 hours.
• Trabectedin powder for reconstitution should be mixed with 20 ml of sterile water of injection, and further diluted with 500 ml of 0.9% sodium chloride or 5% dextrose.
• Do not mix other drugs with trabectedin injection.
• Use the trabectedin solution within 30 hours from the time of reconstitution and discard any unused or remaining solution.
• Trabectedin vials should be checked for any discoloration or presence of visible particles before administering, and if any such things are seen, the vial should be discarded.
• The recommended dose of trabectedin is 1.5mg/m2 given for every three weeks or 21 days up until any disease progression or drug toxicity.
• Patients who are given trabectedin should have normal levels of bilirubin, and the liver enzymes such as AST (SGOT) and ALT (SGPT) should be less than or equal to 2.5 times the standard limit.
• Injection of dexamethasone 20 mg should be given 30 minutes before starting trabectedin infusion to avoid specific side effects such as liver toxicity and vomiting caused by trabectedin.
• The dose of trabectedin can be adjusted based on the side effects that occur during trabectedin treatment, and if reduced should not be increased in the following treatment cycles.
• The dose of trabectedin can be reduced to 1.2 mg/m2 for every three weeks and if side effects tend to occur, the dose can further be reduced to 1 mg/m2 for every three weeks.
• Combination of trabectedin with other drugs should not be used if the creatinine clearance is less than 60 mL/min; monotherapy of trabectedin should not be given if the creatinine clearance is less than 30mL/min.
• Allergic to trabectedin
• Pregnancy and breastfeeding
• Children
• Undergoing treatment for infertility
• High levels of creatine phosphokinase
Caution is required while treating patients with-
• Liver disorder
• Abnormal heart function
• Kidney disease
• Trabectedin powder for reconstitution should be mixed with 20 ml of sterile water of injection, and further diluted with 500 ml of 0.9% sodium chloride or 5% dextrose.
• Do not mix other drugs with trabectedin injection.
• Use the trabectedin solution within 30 hours from the time of reconstitution and discard any unused or remaining solution.
• Trabectedin vials should be checked for any discoloration or presence of visible particles before administering, and if any such things are seen, the vial should be discarded.
Dosage & When it is to be taken
• The dose is calculated based on the patient’s body surface area.• The recommended dose of trabectedin is 1.5mg/m2 given for every three weeks or 21 days up until any disease progression or drug toxicity.
• Patients who are given trabectedin should have normal levels of bilirubin, and the liver enzymes such as AST (SGOT) and ALT (SGPT) should be less than or equal to 2.5 times the standard limit.
• Injection of dexamethasone 20 mg should be given 30 minutes before starting trabectedin infusion to avoid specific side effects such as liver toxicity and vomiting caused by trabectedin.
• The dose of trabectedin can be adjusted based on the side effects that occur during trabectedin treatment, and if reduced should not be increased in the following treatment cycles.
• The dose of trabectedin can be reduced to 1.2 mg/m2 for every three weeks and if side effects tend to occur, the dose can further be reduced to 1 mg/m2 for every three weeks.
• Combination of trabectedin with other drugs should not be used if the creatinine clearance is less than 60 mL/min; monotherapy of trabectedin should not be given if the creatinine clearance is less than 30mL/min.
When it is not to be taken (Contraindications)
Trabectedin should not be used in patients-• Allergic to trabectedin
• Pregnancy and breastfeeding
• Children
• Undergoing treatment for infertility
• High levels of creatine phosphokinase
Caution is required while treating patients with-
• Liver disorder
• Abnormal heart function
• Kidney disease
